Detectiome
Detectiome, founded in 2022, is revolutionizing cancer care with its AI and multiomics-based solutions. Their flagship product, Revonco, is the first multi-cancer early detection test tailored for the unique genetic population of the Middle East. This innovative blood test can detect multiple types of cancer at their earliest stages, significantly improving treatment outcomes. Detectiome aims to address the critical issue of late cancer detection, potentially saving thousands of lives annually in the UAE. With a strong commitment to leveraging technology for health advancements, Detectiome is positioned as a leader in the cancer diagnostics market.
Detectiome
Detectiome, founded in 2022, is revolutionizing cancer care with its AI and multiomics-based solutions. Their flagship product, Revonco, is the first multi-cancer early detection test tailored for the unique genetic population of the Middle East. This innovative blood test can detect multiple types of cancer at their earliest stages, significantly improving treatment outcomes. Detectiome aims to address the critical issue of late cancer detection, potentially saving thousands of lives annually in the UAE. With a strong commitment to leveraging technology for health advancements, Detectiome is positioned as a leader in the cancer diagnostics market.